- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Esteve earmarks $80M to revamp CDMO operations in China | ||
| Do | Pfizer's latest cost-savings plan looks to get early start as layoff reports surface around Europe, US plants | ||
| Do | Roivant comes for Humira as Lisraya checks boxes in inflammatory eye disease phase 3s | ||
| Do | FDA rebukes Baxter over 'repeated' production stumbles in new warning letter | ||
| Do | AI-Powered Brand Sites Are Changing Patient Engagement | ||
| Do | AbbVie pumps up the economic case for early subcutaneous Parkinson's treatment | ||
| Do | Otsuka hit with 11 marketing code breaches after event organizer blunder | ||
| Mi | New US drug launches need price check to counter access impediments, ICER, West Health urge | ||
| Mi | CSL taps GSK's Deborah Waterhouse as CEO in the darkest hour | ||
| Mi | Alcon ponies up $550M for Neurotech, bagging approved cell therapy implant Encelto | ||
| Mi | GSK brings promise of 'functional cure' to hepatitis B finish line with FDA nod for Hibsago | ||
| 20.10. | CDMO Samsung Bio wins temporary reprieve from strike threat after Seoul court ruling | ||
| 20.10. | Antheia lands $80M conditional loan from Trump administration to onshore drug manufacturing | ||
| 20.10. | Cosette lands FDA approval for Evoxac liquid in Sjögren's disease | ||
| 20.10. | AbbVie hits the gas on immunology awareness with McLaren F1 pact | ||
| 20.10. | Veradermics' hot streak continues with another phase 3 win in hair loss | ||
| 20.10. | Amgen, AZ dive deep into Tezspire's Dupixent-challenging victory in EoE phase 3 | ||
| 19.10. | GSK's Jemperli scores FDA approval in rectal cancer, backed by high complete response rate | ||
| 19.10. | EyePoint cuts headcount, shifts priorities after another Duravyu AMD miss | ||
| 19.10. | Roche pauses future Germany investments, joining growing pharma chorus of pullbacks | ||
| 19.10. | Novartis pauses midstage Fabhalta trial in lupus nephritis-but efficacy, safety not at play | ||
| 19.10. | Eli Lilly's Omvoh takes phase 3 win in pediatric UC, fueling expansion ambitions | ||
| 19.10. | The Next Chapter for AI in Clinical Trials | ||
| 19.10. | Closing the gap between approval and treatment | ||
| 16.10. | The Oral GLP-1 Tracker: Foundayo, Wegovy pill undergo minor fluctuations |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.